# Certolizumab pegol

## Cimzia inj 200mg/1mL

| TAH Drug Code      | [ICIM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICIM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Ankylosing spondylitis, Active. Crohn's disease, Active, moderate to severe. Non-radiographic axial spondyloarthritis. Plaque psoriasis, Moderate to severe. Psoriatic arthritis, Active. Rheumatoid arthritis, Active, moderate to severe.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | SC, Ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis 400 mg once and then repeat at weeks 2 and 4; maintenance, 200 mg every 2 weeks or 400 mg once every 4 weeks. Crohn's disease 400 mg (as 2 injections of 200 mg) once and then repeat at weeks 2 and 4; maintenance , 400 mg once every 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | Hypersensitivity to certolizumab pegol or any component of the product. Severe infections or Moderate to severe heart failure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common ‧Musculoskeletal: Arthralgia (6%) ‧Renal: Urinary tract infectious disease (7%) ‧Respiratory: Upper respiratory infection (19.4% to 21.9%) Serious ‧Cardiovascular: Cardiac dysrhythmia, Congestive heart failure, Hypertensive heart disease, Myocardial infarction, Pericardial effusion, Pericarditis ‧Dermatologic: Erythema multiforme, Erythema nodosum, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Urticaria ‧Gastrointestinal: Bowel obstruction ‧Hematologic: Cytopenia ‧Immunologic: Hypersensitivity reaction (Rare ), Lupus erythematosus (Rare ), Malignant lymphoma, Opportunistic infection ‧Neurologic: Demyelinating disease of central nervous system (rare ), Seizure ‧Psychiatric: At risk for suicide ‧Renal: Nephrotic syndrome, Renal failure ‧Other: Cancer, Infectious disease, Listeriosis |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

